PURPOSE: A composition containing 5-HT_3 receptor antagonist and corticosteroid is provided to prevent suppress or treat nausea or vomiting and to enable direct administration without dilution. CONSTITUTION: A composition for preventing nausea or vomiting contains 5-HT_3 receptor antagonist and corticosteroid. The 5-HT_3 receptor antagonist includes ondansetron ramosetron granisetron tropisetron dolasetron palonosetron alosetron lurosetron or derivative or pharmaceutically acceptable salt thereo...

PROBLEM TO BE SOLVED: To provide a treating drug for diarrhea accompanying disease other than diarrhea type IBD (inflammatory bowel disease) in the inflammatory bowel disease patient in an active period, especially for abnormal defecation such as diarrhea observed in an active period of IBD.

The present invention provides an improved process for the preparation of Alosetron of formula (I) and its pharmaceutically acceptable salts.

The present invention provides an improved process for the preparation of Alosetron of formula (I) and its pharmaceutically acceptable salts.

A therapeutic agent for abnormal defecation in an inflammatory bowel disease patient who is in the remission phase, which comprises ramosetron, alosetron or a pharmaceutically acceptable salt thereof as an active ingredient.

Un antagonista del receptor de la 5-HT 3 o bien una sal de dicho antagonista aceptable desde el punto de vista farmacéutico elegida del grupo formado por ondansetron granisetron dolasetron tropisetron ramosetron fabesetron lintopride y alosetron para utilizar: a) en el tratamiento de una enfermedad local no inflamatoria del sistema músculo-esquelético seleccionada del grupo formado por el síndrome miofascial la tendomiosis tendinosis tendopatía de inserción bursopatía o periartropatía síndrome d...

The invention relates to the use of cilansetron for treating non-obstipated male IBS patients and also for treating patients of both sexes who suffer from irritable bowel syndrome (IBS) by administering the pharmaceutical preparation three times a day. In said preparation alosetron azasetron dolasetron granisetron indisetron itasetron lerisetron ondansetron ramosetron tropisetron and/or (R)-zacopride are used as 5HT3 receptor antagonists.

1. A method of treatment of nonconstipated female IBS which comprises administering an effective amount of a 5-HT3 receptor antagonist or a pharmaceutically acceptable derivative thereof selected from the group consisting of alosetron granisetron azasetron tropisetron ramosetron ondansetron lerisetron (R) zacopride cilansetron itasetron indisetron and dolasetron and pharmaceutically acceptable derivatives thereof. 2. A method according to claim 1 wherein the 5-HT3 receptor antagonist a pharmaceu...

This invention relates to the use of alosetron in the treatment of functional dyspepsia.

The invention relates to the use of cilansetron for treating non-obstipated male IBS patients and also for treating patients of both sexes who suffer from irritable bowel syndrome (IBS) by administering the pharmaceutical preparation three times a day. In said preparation alosetron azasetron dolasetron granisetron indisetron itasetron lerisetron ondansetron ramosetron tropisetron and/or (R)-zacopride are used as 5HT3 receptor antagonists.